Jasper Boeddinghaus1,2,3, Raphael Twerenbold1,3,4, Thomas Nestelberger1,3, Patrick Badertscher1,3, Karin Wildi1,3, Christian Puelacher1,3, Jeanne du Fay de Lavallaz1,2,3, Elif Keser1,3, Maria Rubini Giménez1,3, Desiree Wussler1,2,3, Nikola Kozhuharov1,3, Katharina Rentsch5, Òscar Miró3,6, F Javier Martin-Sanchez3,7, Beata Morawiec3,8, Sabrina Stefanelli1, Nicolas Geigy9, Dagmar I Keller10, Tobias Reichlin1,3, Christian Mueller11,3. 1. Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland. 2. Division of Internal Medicine, University Hospital Basel, University of Basel, Basel, Switzerland. 3. GREAT network, Rome, Italy. 4. Department of General and Interventional Cardiology, Hamburg University Heart Center, Hamburg, Germany. 5. Laboratory Medicine, University Hospital Basel, Basel, Switzerland. 6. Emergency Department, Hospital Clinic, Barcelona, Catalonia, Spain. 7. Servicio de Urgencias, Hospital Clínico San Carlos, Madrid, Spain. 8. 2nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Katowice, Katowice, Poland. 9. Emergency Department, Kantonsspital Liestal, Switzerland. 10. Emergency Department, University Hospital Zurich, Zurich, Switzerland. 11. Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland; christian.mueller@usb.ch.
Abstract
BACKGROUND: Clinical performance of the novel high-sensitivity cardiac troponin I (Siemens-hs-cTnI-Centaur) assay is unknown. We aimed to clinically validate the Siemens-hs-cTnI-Centaur assay and develop 0/1-h and 0/2-h algorithms. METHODS: We enrolled patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by 2 independent cardiologists including all clinical information twice: first, using serial hs-cTnT (Roche-Elecsys, primary analysis); second, using hs-cTnI (Abbott-Architect, secondary analysis) measurements in addition to the clinically applied (hs)-cTn. Siemens-hs-cTnI-Centaur was measured at presentation, 1 h, and 2 h. The primary objective was a direct comparison of diagnostic accuracy, quantified by the area under the ROC curve (AUC), of Siemens-hs-cTnI-Centaur vs the 2 established hs-cTn assays (Roche-hs-cTnT-Elecsys, Abbott-hs-cTnI-Architect). Secondary objectives included the development of Siemens-hs-cTnI-Centaur-specific 0/1-h and 0/2-h algorithms. RESULTS: AMI was the final diagnosis in 318 of 1755 (18%) patients (using Roche-hs-cTnT-Elecsys for adjudication). The AUC at presentation for Siemens-hs-cTnI-Centaur was 0.94 (95% CI, 0.92-0.96) and comparable with 0.95 (95% CI, 0.93-0.97) for Roche-hs-cTnT-Elecsys and 0.93 (95% CI, 0.90-0.96) for Abbott-hs-cTnI-Architect. Applying the derived Siemens-hs-cTnI-Centaur 0/1-h algorithm to the validation cohort, 46% of patients were ruled out (sensitivity, 99.1%; 95% CI, 95.3-100), and 18% of patients were ruled in (specificity, 94.1%; 95% CI, 91.8-95.9). The Siemens-hs-cTnI-Centaur 0/2-h algorithm ruled out 55% of patients (sensitivity, 100%; 95% CI, 94.1-100), and ruled in 18% of patients (specificity, 96.0%; 95% CI, 93.1-97.9). Findings were confirmed in the secondary analyses using serial measurements of Abbott-hs-cTnI-Architect for adjudication. CONCLUSIONS: Diagnostic accuracy and clinical utility of the novel Siemens-hs-cTnI-Centaur assay are high and comparable with the established hs-cTn assays. ClinicalTrials.gov Identifier: NCT00470587.
BACKGROUND: Clinical performance of the novel high-sensitivity cardiac troponin I (Siemens-hs-cTnI-Centaur) assay is unknown. We aimed to clinically validate the Siemens-hs-cTnI-Centaur assay and develop 0/1-h and 0/2-h algorithms. METHODS: We enrolled patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by 2 independent cardiologists including all clinical information twice: first, using serial hs-cTnT (Roche-Elecsys, primary analysis); second, using hs-cTnI (Abbott-Architect, secondary analysis) measurements in addition to the clinically applied (hs)-cTn. Siemens-hs-cTnI-Centaur was measured at presentation, 1 h, and 2 h. The primary objective was a direct comparison of diagnostic accuracy, quantified by the area under the ROC curve (AUC), of Siemens-hs-cTnI-Centaur vs the 2 established hs-cTn assays (Roche-hs-cTnT-Elecsys, Abbott-hs-cTnI-Architect). Secondary objectives included the development of Siemens-hs-cTnI-Centaur-specific 0/1-h and 0/2-h algorithms. RESULTS: AMI was the final diagnosis in 318 of 1755 (18%) patients (using Roche-hs-cTnT-Elecsys for adjudication). The AUC at presentation for Siemens-hs-cTnI-Centaur was 0.94 (95% CI, 0.92-0.96) and comparable with 0.95 (95% CI, 0.93-0.97) for Roche-hs-cTnT-Elecsys and 0.93 (95% CI, 0.90-0.96) for Abbott-hs-cTnI-Architect. Applying the derived Siemens-hs-cTnI-Centaur 0/1-h algorithm to the validation cohort, 46% of patients were ruled out (sensitivity, 99.1%; 95% CI, 95.3-100), and 18% of patients were ruled in (specificity, 94.1%; 95% CI, 91.8-95.9). The Siemens-hs-cTnI-Centaur 0/2-h algorithm ruled out 55% of patients (sensitivity, 100%; 95% CI, 94.1-100), and ruled in 18% of patients (specificity, 96.0%; 95% CI, 93.1-97.9). Findings were confirmed in the secondary analyses using serial measurements of Abbott-hs-cTnI-Architect for adjudication. CONCLUSIONS: Diagnostic accuracy and clinical utility of the novel Siemens-hs-cTnI-Centaur assay are high and comparable with the established hs-cTn assays. ClinicalTrials.gov Identifier: NCT00470587.
Authors: Matthew T H Lowry; Dimitrios Doudesis; Ryan Wereski; Dorien M Kimenai; Christopher Tuck; Amy V Ferry; Anda Bularga; Caelan Taggart; Kuan K Lee; Andrew R Chapman; Anoop S V Shah; David E Newby; Nicholas L Mills; Atul Anand Journal: Circulation Date: 2022-09-15 Impact factor: 39.918
Authors: Júlia Karády; Thomas Mayrhofer; Maros Ferencik; John T Nagurney; James E Udelson; Andreas A Kammerlander; Jerome L Fleg; W Frank Peacock; James L Januzzi; Wolfgang Koenig; Udo Hoffmann Journal: J Am Coll Cardiol Date: 2021-03-30 Impact factor: 24.094
Authors: Nisha Bansal; Leila R Zelnick; Christie M Ballantyne; Paulo H M Chaves; Robert H Christenson; Josef Coresh; Christopher R deFilippi; James A de Lemos; Lori B Daniels; Alan S Go; Jiang He; S Susan Hedayati; Kunihiro Matsushita; Vijay Nambi; Michael G Shlipak; Jonathan J Taliercio; Stephen L Seliger Journal: Am J Kidney Dis Date: 2021-07-19 Impact factor: 8.860
Authors: Bernard Cook; James McCord; Michael Hudson; Waleed Al-Darzi; Michele Moyer; Gordon Jacobsen; Richard Nowak Journal: Crit Pathw Cardiol Date: 2021-03-01
Authors: Danielle M Gualandro; Christian Puelacher; Giovanna Lurati Buse; Noemi Glarner; Francisco A Cardozo; Ronja Vogt; Reka Hidvegi; Celia Strunz; Daniel Bolliger; Johanna Gueckel; Pai C Yu; Marcel Liffert; Ketina Arslani; Alexandra Prepoudis; Daniela Calderaro; Angelika Hammerer-Lercher; Andreas Lampart; Luzius A Steiner; Stefan Schären; Christoph Kindler; Lorenz Guerke; Stefan Osswald; P J Devereaux; Bruno Caramelli; Christian Mueller Journal: Clin Res Cardiol Date: 2021-03-25 Impact factor: 5.460
Authors: Andrew R Chapman; Takeshi Fujisawa; Kuan Ken Lee; Jack Patrick Andrews; Atul Anand; Dennis Sandeman; Amy V Ferry; Stacey Stewart; Lucy Marshall; Fiona E Strachan; Alasdair Gray; David E Newby; Anoop S V Shah; Nicholas L Mills Journal: Heart Date: 2018-11-15 Impact factor: 5.994